• SARS-CoV-2

    Surrogate virus neutralisation test from EUROIMMUN


  • Surrogate virus neutralisation test (sVNT) for semi-quantitative detection of neutralising antibodies inhibiting the binding of SARS-CoV-2 S1/RBD to ACE2 receptors of the host cells
  • Supports the evaluation of the immune response after SARS-CoV-2 infection or vaccination using S1/RBD-based vaccines
  • Very high agreement of results compared with a plaque reduction neutralisation test (PRNT50)
  • Established ELISA method – suitable for routine laboratory diagnostics, no BSL-3 laboratory required
  • Automatable even for high-throughput analysis, results available in approx. 2 hours
  • Modelled upon nature: Neutralising antibodies in the sample compete with the host-cell receptor (ACE2) for the binding to S1/RBD in the first incubation step, no preadsorption required
  • Multispecies test- application with animal specimen possible for research use only


ProductFormatIncluded controlsOrder no.Status
ELISA 96 x 01 pos. control, neg. control

EI 2606-9601-4




Options for automated processing of the EUROIMMUN ELISA

1. EUROIMMUN Automation Solutions:

EUROLabWorkstation ELISA, Analyzer I, Analyzer I-2P and Sprinter XL

For further information on our automation options, please contact our experts of product management for instruments and software.

2. Processing on all common open ELISA platforms

Anti-SARS-CoV-2 ELISA IgG / Anti-SARS-CoV-2 QuantiVac ELISA (IgG)

  • Specific detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein including the immunologically relevant receptor binding domain (RBD)
  • RBD represents important target antigen for virus neutralising antibodies
  • Worldwide programs for vaccine development use the spike protein as antigen
  • Available as ELISA for semi-quantitative and quantitative determination (same cut-off calibrator); quantitative results can NOW be given in standardised units!
  • Excellent performance and good correlation with different test systems for the detection of neutralising antibodies confirmed in external studies
  • Validated for serum, plasma and dried capillary blood as sample material, complete automation possible

Customer comments and testimonials about SARS-CoV-2 ELISA (IgG)


ProductIg classFormatIncluded controlsOrder no.Status
Anti-SARS-CoV-2 ELISA IgG96 x 01
96 x 20
pos. control, neg. controlEI 2606-9601 G
EI 2606-9620 G*
Anti-SARS-CoV-2 QuantiVac ELISA (IgG)IgG96 x 01EI 2606-9601-10 GCE-marked

*Optimized for processing with the EUROLabWorkstation ELISA